Do we really need prognostic factors for breast cancer?
- 1 January 1994
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 30 (2) , 117-126
- https://doi.org/10.1007/bf00666054
Abstract
The role of prognostic factors in optimizing treatment for breast cancer patients has clearly changed with the trend toward general use of adjuvant therapy. Nevertheless, there are at least three situations in which prognostic factors could be helpful. The first is to identify patients whose prognosis is so good that adjuvant therapy after local surgery would not be cost-beneficial. The second is to identify patients whose prognosis is so poor that a more aggressive adjuvant approach would be warranted. The third is to identify patients likely to be responsive or resistant to particular forms of therapy. Here we will discuss all of these situations, together with the appropriate cutpoint analyses and validation of individual prognostic factors and their combination into prognostic indexes which may make the discrimination of patient subsets more reliable.Keywords
This publication has 22 references indexed in Scilit:
- Heat Shock Protein hsp70 in Patients With Axillary Lymph Node-Negative Breast Cancer: Prognostic ImplicationsJNCI Journal of the National Cancer Institute, 1993
- The Nottingham prognostic index in primary breast cancerBreast Cancer Research and Treatment, 1992
- Why do so many prognostic factors fail to pan out?Breast Cancer Research and Treatment, 1992
- Response of human breast cancer cells to heat shock and chemotherapeutic drugs.1992
- Prognostic Factors and Treatment Decisions in Axillary-Node-Negative Breast CancerNew England Journal of Medicine, 1992
- Breast cancer treatment and natural history: new insights from results of screeningThe Lancet, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Treatment of Early-Stage Breast CancerJAMA, 1991
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987